Slingshot Insights | Ipn.pa Overview

IPN.PA Overview

Upcoming Projects (IPN.PA)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (IPN.PA)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (IPN.PA)

After its recent IPO we look at Crinetics’ lead pipeline candidate, CRN00808, in treating Acromegaly
Tickers: CRNX, NVS, IPN.PA
Execute By: Nov 07, 2018
What exactly constitutes a sale? Digging into the change of control claims from MACK's Convertible note holders after the ONVYDE asset sale to Ipsen
Tickers: MACK, IPN.PA
Execute By: Jul 14, 2017

Upcoming & Overdue Catalysts (IPN.PA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (IPN.PA)

Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older
Ticker: IPN.PA
Occurred on: Aug 01, 2016
Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
Tickers: EXEL, IPN.PA
Occurred on: Jul 22, 2016

Strategic Initiatives (IPN.PA)

Don’t see a strategic initiative related to the company you care about? Create your own!